...
首页> 外文期刊>npj Digital Medicine >Developing and adopting safe and effective digital biomarkers to improve patient outcomes
【24h】

Developing and adopting safe and effective digital biomarkers to improve patient outcomes

机译:开发和采用安全有效的数字生物标志物,以改善患者结果

获取原文
           

摘要

Biomarkers are physiologic, pathologic, or anatomic characteristics that are objectively measured and evaluated as an indicator of normal biologic processes, pathologic processes, or biological responses to therapeutic interventions. Recent advances in the development of mobile digitally connected technologies have led to the emergence of a new class of biomarkers measured across multiple layers of hardware and software. Quantified in ones and zeros, these “digital” biomarkers can support continuous measurements outside the physical confines of the clinical environment. The modular software–hardware combination of these products has created new opportunities for patient care and biomedical research, enabling remote monitoring and decentralized clinical trial designs. However, a systematic approach to assessing the quality and utility of digital biomarkers to ensure an appropriate balance between their safety and effectiveness is needed. This paper outlines key considerations for the development and evaluation of digital biomarkers, examining their role in clinical research and routine patient care.
机译:生物标志物是经客观测量和评估为正常生物过程,病理过程或治疗干预的生物反应的指标的生理学,病理学或解剖学特征。最近在移动数字连接技术的发展的进展导致了在多层硬件和软件上测量的新类生物标志物的出现。在那些和零中量化,这些“数字”生物标志物可以支持临床环境的物理范围之外的连续测量。这些产品的模块化软件 - 硬件组合为患者护理和生物医学研究创造了新的机会,实现了远程监测和分散的临床试验设计。但是,评估数字生物标志物的质量和效用的系统方法,以确保其安全性和有效性之间的适当平衡。本文概述了数字生物标志物的开发和评估的关键考虑,研究了它们在临床研究和常规患者护理中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号